Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
PTX's Cash to Debt is ranked lower than
88% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. PTX: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
PTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.51 Max: No Debt
Current: 0.17
Equity to Asset 0.07
PTX's Equity to Asset is ranked lower than
97% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. PTX: 0.07 )
Ranked among companies with meaningful Equity to Asset only.
PTX' s Equity to Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.43 Max: 0.77
Current: 0.07
0.07
0.77
F-Score: 3
Z-Score: -0.73
M-Score: -3.46
WACC vs ROIC
12.09%
-31.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -57.58
PTX's Operating margin (%) is ranked lower than
87% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. PTX: -57.58 )
Ranked among companies with meaningful Operating margin (%) only.
PTX' s Operating margin (%) Range Over the Past 10 Years
Min: -64.4  Med: -2.75 Max: 28.95
Current: -57.58
-64.4
28.95
Net-margin (%) -84.34
PTX's Net-margin (%) is ranked lower than
89% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. PTX: -84.34 )
Ranked among companies with meaningful Net-margin (%) only.
PTX' s Net-margin (%) Range Over the Past 10 Years
Min: -84.34  Med: -15.64 Max: 28.02
Current: -84.34
-84.34
28.02
ROE (%) -179.05
PTX's ROE (%) is ranked lower than
97% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. PTX: -179.05 )
Ranked among companies with meaningful ROE (%) only.
PTX' s ROE (%) Range Over the Past 10 Years
Min: -254.21  Med: -4.32 Max: 76.9
Current: -179.05
-254.21
76.9
ROA (%) -27.87
PTX's ROA (%) is ranked lower than
85% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. PTX: -27.87 )
Ranked among companies with meaningful ROA (%) only.
PTX' s ROA (%) Range Over the Past 10 Years
Min: -29.99  Med: -2.32 Max: 31.32
Current: -27.87
-29.99
31.32
ROC (Joel Greenblatt) (%) -1546.93
PTX's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. PTX: -1546.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5335.54  Med: -9.14 Max: 365.09
Current: -1546.93
-5335.54
365.09
Revenue Growth (3Y)(%) 14.80
PTX's Revenue Growth (3Y)(%) is ranked higher than
77% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. PTX: 14.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -14.30 Max: 105.3
Current: 14.8
0
105.3
EPS Growth (3Y)(%) 281.80
PTX's EPS Growth (3Y)(%) is ranked higher than
100% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. PTX: 281.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PTX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -63.20 Max: 281.8
Current: 281.8
0
281.8
» PTX's 10-Y Financials

Financials (Next Earnings Date: 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PTX Guru Trades in Q1 2015

Paul Tudor Jones 49,500 sh (New)
» More
Q2 2015

PTX Guru Trades in Q2 2015

Steven Cohen 525,000 sh (New)
Jim Simons 57,021 sh (New)
Paul Tudor Jones 75,800 sh (+53.13%)
» More
Q3 2015

PTX Guru Trades in Q3 2015

Jim Simons 463,602 sh (+713.04%)
Steven Cohen 1,050,005 sh (+100.00%)
Paul Tudor Jones Sold Out
» More
Q4 2015

PTX Guru Trades in Q4 2015

Paul Tudor Jones 16,134 sh (New)
Jim Simons 847,823 sh (+82.88%)
Steven Cohen 1,050,005 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 1.83
PTX's Forward P/E is ranked higher than
99% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. PTX: 1.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.80
PTX's P/B is ranked higher than
78% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. PTX: 1.80 )
Ranked among companies with meaningful P/B only.
PTX' s P/B Range Over the Past 10 Years
Min: 0.26  Med: 1.75 Max: 14.69
Current: 1.8
0.26
14.69
P/S 0.30
PTX's P/S is ranked higher than
96% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. PTX: 0.30 )
Ranked among companies with meaningful P/S only.
PTX' s P/S Range Over the Past 10 Years
Min: 0.07  Med: 1.60 Max: 8.94
Current: 0.3
0.07
8.94
EV-to-EBITDA 33.00
PTX's EV-to-EBITDA is ranked lower than
75% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. PTX: 33.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.6  Med: 9.20 Max: 280.5
Current: 33
-80.6
280.5
Current Ratio 1.17
PTX's Current Ratio is ranked lower than
83% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. PTX: 1.17 )
Ranked among companies with meaningful Current Ratio only.
PTX' s Current Ratio Range Over the Past 10 Years
Min: 0.09  Med: 1.43 Max: 2.16
Current: 1.17
0.09
2.16
Quick Ratio 1.10
PTX's Quick Ratio is ranked lower than
72% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. PTX: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
PTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.07  Med: 1.29 Max: 1.96
Current: 1.1
0.07
1.96
Days Inventory 75.23
PTX's Days Inventory is ranked higher than
73% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. PTX: 75.23 )
Ranked among companies with meaningful Days Inventory only.
PTX' s Days Inventory Range Over the Past 10 Years
Min: 72.83  Med: 122.48 Max: 220.74
Current: 75.23
72.83
220.74
Days Sales Outstanding 121.85
PTX's Days Sales Outstanding is ranked lower than
77% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. PTX: 121.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.95  Med: 124.07 Max: 208.1
Current: 121.85
22.95
208.1
Days Payable 99.98
PTX's Days Payable is ranked higher than
66% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. PTX: 99.98 )
Ranked among companies with meaningful Days Payable only.
PTX' s Days Payable Range Over the Past 10 Years
Min: 28.65  Med: 78.77 Max: 126.23
Current: 99.98
28.65
126.23

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 9.80
PTX's Price/Projected FCF is ranked lower than
74% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. PTX: 9.80 )
Ranked among companies with meaningful Price/Projected FCF only.
PTX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.46  Med: 3.13 Max: 29.5
Current: 9.8
0.46
29.5
Price/Median PS Value 0.18
PTX's Price/Median PS Value is ranked higher than
98% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. PTX: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
PTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 1.18 Max: 4.04
Current: 0.18
0.13
4.04
Price/Graham Number 0.06
PTX's Price/Graham Number is ranked higher than
99% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. PTX: 0.06 )
Ranked among companies with meaningful Price/Graham Number only.
PTX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.17  Med: 1.25 Max: 5.38
Current: 0.06
0.17
5.38
Earnings Yield (Greenblatt) (%) -31.05
PTX's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. PTX: -31.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -31.05  Med: 6.00 Max: 16.7
Current: -31.05
-31.05
16.7

More Statistics

Revenue(Mil) $176
EPS $ -2.76
Beta2.43
Short Percentage of Float8.85%
52-Week Range $0.73 - 7.10
Shares Outstanding(Mil)61.13

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 196 222 230
EPS($) 0.09 0.41 0.40
EPS without NRI($) 0.09 0.41 0.40

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XKRX:053950, NAS:CPIX, HKSE:00932, ROCO:6553, BOM:524164, HKSE:01889 » details
Traded in other countries:GTAP.Germany,
Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumberland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.
» More Articles for PTX

Headlines

Articles On GuruFocus.com
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Dollar in focus as stocks rebound to start week May 02 2016
This Pharma Company is Soaring After Steve Cohen Boosts Stake, GrubHub Inc. (GRUB) Has a Bullish New... May 02 2016
Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016 Apr 29 2016
PERNIX THERAPEUTICS TO REPORT FIRST QUARTER 2016 FINANCIAL RESULTS ON THURSDAY, MAY 5, 2016 Apr 28 2016
Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016 Apr 28 2016
Government Spending On Opioid Epidemic Creates Surprising Beneficiary Apr 28 2016
ETF’s with exposure to Pernix Therapeutics Holdings, Inc. : April 14, 2016 Apr 14 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 05 2016
Pernix Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference Apr 05 2016
Pernix Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference Apr 05 2016
ETF’s with exposure to Pernix Therapeutics Holdings, Inc. : March 24, 2016 Mar 24 2016
6 Biotech Stocks Under $10 to Trade for Big Breakouts Mar 23 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Financials Mar 16 2016
ETF’s with exposure to Pernix Therapeutics Holdings, Inc. : March 14, 2016 Mar 14 2016
Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 14 2016
Pernix Therapeutics downgraded by Needham Mar 11 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-K, Annual Report Mar 10 2016
Pernix Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update Mar 10 2016
Q4 2015 Pernix Therapeutics Holdings Inc Earnings Release - Before Market Open Mar 10 2016
Pernix Therapeutics Files Citizen Petition Following Issuance of U.S. Patent Number 9,265,760... Mar 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK